Evogene Ltd. (TLV:EVGN)

-82.64% (1Y)

Market Cap	32.01M
Revenue (ttm)	31.00M
Net Income (ttm)	-60.04M
Shares Out	6.51M
EPS (ttm)	-10.54
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,730
Average Volume	10,275
Open	485.00
Previous Close	484.10
Day's Range	481.60 - 485.00
52-Week Range	450.10 - 2,989.00
Beta	1.11
RSI	38.16
Earnings Date	Mar 6, 2025

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health, agriculture, and other industrial applications through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. The Huma...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 142
• Stock Exchange: Tel Aviv Stock Exchange
• Ticker Symbol: EVGN

Financial Performance

In 2024, Evogene's revenue was $8.51 million, an increase of 50.90% compared to the previous year's $5.64 million. Losses were -$16.49 million, -30.96% less than in 2023.

Financial numbers in USD